GRDN

Guardian Pharmacy Services, Inc.

8 filings tracked

healthcarepharmaceuticalsSMALL ($300M-2B)

Signal Magnitude Chart

bullish

bearish

neutral

Signal Timeline

bullishMay 28

Extended debt maturity to 2030 and increased borrowing capacity to $80 million.

debt restructure

70%

neutralMay 28

Permitted addition of up to $40 million in incremental term loans.

capital raise

50%

bullishMay 6

Net income increased significantly to $13.3 million from $9.4 million YoY.

earnings beat

70%

bullishMay 6

Gross margin improved from 19.5% to 22.7% due to lower product costs.

margin expansion

60%

bearishMay 6

SG&A expenses rose 14.2%, increasing the expense ratio to 17.4% of revenue.

margin compression

50%

neutralMay 6

Growth heavily reliant on 2025 acquisitions to offset organic revenue declines.

acquisition

40%

bullishMay 6

Net income increased significantly to $13.3 million from $9.4 million YoY.

earnings beat

70%

bullishMay 6

Gross margin improved from 19.5% to 22.7% due to lower product costs.

margin expansion

60%

bearishMay 6

SG&A expenses rose 14.2%, increasing the expense ratio to 17.4% of revenue.

margin compression

50%

neutralMay 6

Growth heavily reliant on 2025 acquisitions to offset organic revenue declines.

acquisition

40%

bullishMay 6

Net income increased significantly to $13.3 million from $9.4 million YoY.

earnings beat

70%

bullishMay 6

Gross margin improved from 19.5% to 22.7% due to lower product costs.

margin expansion

60%

bearishMay 6

SG&A expenses rose 14.2%, increasing the expense ratio to 17.4% of revenue.

margin compression

50%

neutralMay 6

Growth heavily reliant on 2025 acquisitions to offset organic revenue declines.

acquisition

40%

bullishMay 6

Net income increased significantly to $13.3 million from $9.4 million YoY.

earnings beat

70%

bullishMay 6

Gross margin improved from 19.5% to 22.7% due to lower product costs.

margin expansion

60%

bearishMay 6

SG&A expenses rose 14.2%, increasing the expense ratio to 17.4% of revenue.

margin compression

50%

neutralMay 6

Growth heavily reliant on 2025 acquisitions to offset organic revenue declines.

acquisition

40%

bullishMay 6

Net income increased significantly to $13.3 million from $9.4 million YoY.

earnings beat

70%

bullishMay 6

Gross margin improved from 19.5% to 22.7% due to lower product costs.

margin expansion

60%

bearishMay 6

SG&A expenses rose 14.2%, increasing the expense ratio to 17.4% of revenue.

margin compression

50%

neutralMay 6

Growth heavily reliant on 2025 acquisitions to offset organic revenue declines.

acquisition

40%

bullishMay 6

Net income increased significantly to $13.3 million from $9.4 million YoY.

earnings beat

70%

bullishMay 6

Gross margin improved from 19.5% to 22.7% due to lower product costs.

margin expansion

60%

bearishMay 6

SG&A expenses rose 14.2%, increasing the expense ratio to 17.4% of revenue.

margin compression

50%

neutralMay 6

Growth heavily reliant on 2025 acquisitions to offset organic revenue declines.

acquisition

40%

bullishMay 6

Net income increased significantly to $13.3 million from $9.4 million YoY.

earnings beat

70%

bullishMay 6

Gross margin improved from 19.5% to 22.7% due to lower product costs.

margin expansion

60%

bearishMay 6

SG&A expenses rose 14.2%, increasing the expense ratio to 17.4% of revenue.

margin compression

50%

neutralMay 6

Growth heavily reliant on 2025 acquisitions to offset organic revenue declines.

acquisition

40%

Filing History

8-KMay 28, 2026

The 8-K filing reveals a pivotal shift in Guardian Pharmacy Services' capital structure, transitioning its borrowing status to reflect its public company identity and extending its liquidity horizon. The primary tension for investors lies in whether the increased borrowing capacity is a tool for prudent growth or a necessity for survival. While the extended maturity date provides a clear operational window, the increased leverage and modified covenants introduce a higher degree of financial risk that will be closely tied to the company's ability to integrate new acquisitions profitably.

10-QMay 6, 2026

The Q1 2026 filing presents a company at a crossroads between aggressive scale-driven growth and tightening regulatory constraints. On one hand, Guardian is successfully expanding its footprint, increasing its resident count to 207,000 and prescriptions dispensed to 7.4 million. This volume growth has provided a cushion that allowed the company to report an increase in Adjusted EBITDA to $29.8 million, suggesting that the business model can still generate significant cash despite pricing pressures. However, the divergence between GAAP net income growth and the sharp decline in operating cash flow suggests a potential quality-of-earnings issue. The company is essentially trading cash for growth, with working capital needs rising as it integrates acquisitions and navigates new reimbursement landscapes. Investors must now weigh the company's ability to maintain its specialized market moat against the systemic risk of continued drug price reductions and the operational drag of increasing overhead costs.